{"nctId":"NCT01029340","briefTitle":"Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A","startDateStruct":{"date":"2009-12"},"conditions":["Blood Coagulation Disorders","Hemophilia A"],"count":74,"armGroups":[{"label":"Arm 1: Recombinant Factor VIII (BAY81-8973) then Kogenate FS","type":"EXPERIMENTAL","interventionNames":["Biological: Recombinant Factor VIII (BAY81-8973)"]},{"label":"Arm 2: Kogenate FS then Recombinant Factor VIII (BAY81-8973)","type":"EXPERIMENTAL","interventionNames":["Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)"]},{"label":"Arm 3: Recombinant Factor VIII by CS/EP then by CS/ADJ","type":"EXPERIMENTAL","interventionNames":["Biological: Recombinant Factor VIII (BAY81-8973)"]},{"label":"Arm 4: Recombinant Factor VIII by CS/ADJ then by CS/EP","type":"EXPERIMENTAL","interventionNames":["Biological: Recombinant Factor VIII (BAY81-8973)"]},{"label":"Arm 5: Recombinant Factor VIII by CS/EP","type":"EXPERIMENTAL","interventionNames":["Biological: Recombinant Factor VIII (BAY81-8973)"]}],"interventions":[{"name":"Recombinant Factor VIII (BAY81-8973)","otherNames":[]},{"name":"Recombinant Factor VIII (Kogenate FS, BAY14-2222)","otherNames":[]},{"name":"Recombinant Factor VIII (BAY81-8973)","otherNames":[]},{"name":"Recombinant Factor VIII (BAY81-8973)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male, aged 12 to 65 years\n* Severe hemophilia A defined as \\< 1% FVIII:C\n* \\>/= 150 days of previous treatment with FVIII in lifetime\n* Currently receiving on-demand or any type of prophylaxis treatment regimen with any FVIII product\n* No history of or current FVIII inhibitors\n\nExclusion Criteria:\n\n* Presence of another bleeding disease that is different from hemophilia A (e.g., von Willebrand disease, hemophilia B)\n* Low platelet count, abnormal kidney function, or liver disease\n* Received treatment with immune suppressing drugs within the last 3 months prior or requires treatment during the study. (Some drugs for hepatitis C, Human immunodeficiency virus (HIV), and steroids are allowed)\n* Receiving or has received other experimental drugs within 3 months prior to study entry\n* Allergy to Factor VIII or hamsters or mouse protein","healthyVolunteers":false,"sex":"MALE","minimumAge":"12 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part A - Area Under the Drug Concentration-time Curve (AUC)","description":"To examine the Pharmacokinetic (PK) characteristics of BAY 81-8973 and ensure that the new drug is similar to Kogenate FS. All results are based on the chromogenic assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1889.23","spread":"36.11"},{"groupId":"OG001","value":"1583.91","spread":"39.89"}]}]}]},{"type":"PRIMARY","title":"Part A - Half-life (t 1/2)","description":"To examine the PK characteristics of BAY81-8973 and ensure that the new drug is similar to Kogenate FS. All results are based on the chromogenic assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.77","spread":"28.00"},{"groupId":"OG001","value":"12.00","spread":"28.20"}]}]}]},{"type":"PRIMARY","title":"Part B - Annualized Number of Total Bleeds","description":"The annualized number of bleeds experienced by participants","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B - The in Vivo Recovery Values of Human Factor VIII (FVIII)","description":"The amount of Factor VIII found in blood samples taken after the injection of the study drug at the beginning of the CS/EP treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B - Annualized Number of Bleeds in Each 6-month Potency Assignment Period","description":"The annualized number of bleeds experienced by participants in each of the two treatment periods","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B - Control of Bleeding as Measured by the Number of Injections Required to Treat a Bleed","description":"The number of injections needed by participants to stop a bleed","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B - Changes From Baseline at 12 Months in Quality of Life (QoL) as Measured by Transformed Total Score of Haemo-QoL Questionnaire","description":"A measure of how treatment with BAY81-8973 affected the daily life of participants. the scoring system has 100 points. 0 is the worst possible score. 100 is the best possible score. Positive changes from baseline indicate an improvement in quality of life and negative changes indicate a deterioration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.02","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B - Changes From Baseline at 12 Months in Utility Index as Measured by EQ-5D Questionaire","description":"A measure of how treatment with BAY81-8973 affected the daily life of participants. 1.0 = Best possible score, -0.594 = Worst possible score. Positive changes from baseline indicate an improvement and negative changes indicate a deterioration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A - Number of Participants With Inhibitory Antibody Formation","description":"A test to ensure that participants have not developed antibodies that will interfere with the action of BAY81-8973","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B - Number of Participants With Incidence of Inhibitory Antibody Formation","description":"A test to ensure that participants have not developed antibodies that will interfere with the action of BAY81-8973","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part C - Number of Participants With Incidence of Inhibitory Antibody Formation","description":"A test to ensure that participants have not developed antibodies that will interfere with the action of BAY81-8973","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)","description":"A test to analyze the formation of antibodies to HSP-70","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)","description":"A test to analyze the formation of antibodies to HSP-70","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Part C - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)","description":"A test to analyze the formation of antibodies to HSP-70","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)","description":"A test to ensure that participants have not developed antibodies to HCP during the study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)","description":"A test to ensure that participants have not developed antibodies to HCP during the study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part C - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)","description":"A test to ensure that participants have not developed antibodies to HCP during the study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B - Number of Participants With Assessment of the Hemostasis During Major Surgery","description":"An assessment made by surgeons of how effective BAY81-8973 was in stopping bleeding during major operations","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part C - Number of Participants With Assessment of the Hemostasis During Major Surgery","description":"An assessment made by surgeons of how effective BAY81-8973 was in stopping bleeding during major operations","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Diarrhoea","Influenza","Arthralgia"]}}}